# The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention

> **NCT00133731** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 947 (actual)

## Conditions studied

- Angioplasty, Transluminal, Percutaneous Coronary

## Interventions

- **DRUG:** Otamixaban (XRP0673)
- **DRUG:** Unfractionated Heparin
- **PROCEDURE:** Percutaneous Coronary Intervention

## Key facts

- **NCT ID:** NCT00133731
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** —
- **Final completion:** 2005-10
- **Target enrollment:** 947 (ACTUAL)
- **Last updated:** 2008-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00133731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00133731, "The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00133731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*